Source link : https://www.newshealth.biz/health-news/fda-approves-lebrikizumab-for-atopic-dermatitis/
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years and older who have moderate-to-severe atopic dermatitis (AD) that is not well controlled, despite treatment with topical prescription therapies. Candidates for the injectable drug must weigh at least 88 […]
Author : News Health
Publish date : 2024-09-14 13:59:49
Copyright for syndicated content belongs to the linked Source.